Novavax Submits Application To European Medicines Agency For Updated Protein-Based 2024-2025 Formula COVID-19 Vaccine
Portfolio Pulse from Benzinga Newsdesk
Novavax has submitted an application to the European Medicines Agency for an updated COVID-19 vaccine formula for 2024-2025. The JN.1 vaccine targets current circulating strains and is intended for individuals aged 12 and older.
June 24, 2024 | 1:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novavax has filed for a type II variation of its Marketing Authorization with the EMA for its updated JN.1 COVID-19 vaccine. This move aligns with EMA and WHO guidance to target current strains.
The submission to the EMA for an updated COVID-19 vaccine formula is a significant regulatory step. If approved, it could enhance Novavax's market position and revenue potential, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100